Document is current
Any future updates will be listed below
-
Authors
Hunold, Pascal https://orcid.org/0000-0002-7087-5908
Pizzolato, Giulia
Heramvand, Nadia
Kaiser, Laura https://orcid.org/0000-0002-3212-576X
Barbiera, Giulia
van Ray, Olivia
Thomas, Roman https://orcid.org/0000-0001-9132-4876
George, Julie https://orcid.org/0000-0002-4272-3683
Peifer, Martin https://orcid.org/0000-0002-5243-5503
Hänsel-Hertsch, Robert https://orcid.org/0000-0002-2835-4471
- License Information
-
More Information
Article History
Received: 6 September 2024
Accepted: 2 July 2025
First Online: 28 July 2025
Competing interests
: R.K.T. is a founder of PearlRiver Bio (now part of Centessa), a shareholder of Centessa, founder and shareholder of Epiphanes Inc. and a consultant to PearlRiver Bio and Epiphanes Inc. R.K.T. has received research support from Roche. J.G. is consultant to DISCO Pharmaceuticals and received honoraria from MSD and Boehringer Ingelheim. The remaining authors declare no competing interests.
